ES2109796T3 - DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT. - Google Patents

DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT.

Info

Publication number
ES2109796T3
ES2109796T3 ES95810271T ES95810271T ES2109796T3 ES 2109796 T3 ES2109796 T3 ES 2109796T3 ES 95810271 T ES95810271 T ES 95810271T ES 95810271 T ES95810271 T ES 95810271T ES 2109796 T3 ES2109796 T3 ES 2109796T3
Authority
ES
Spain
Prior art keywords
protein
alkyl
pirrolopirimidilo
antiproliferante
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95810271T
Other languages
Spanish (es)
Inventor
Peter Dr Traxler
Pascal Dr Furet
Wolfgang K D Dr Brill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2109796T3 publication Critical patent/ES2109796T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Use of pyrrolo(2,3-d)pyrimidine derivs. of formula (I) or their salts to prepare medicaments for treatment of tumours and other proliferative diseases, disorders of the immune system mediated by protein-tyrosine and/or protein-threonine kinases, and disorders of the central and peripheral nervous system involving signal transmission by protein-tyrosine and/or protein-threonine kinases, is new: n = 0-5; R = halo, alkyl, CF3 or alkoxy; and R1,R2 = H, alkyl, or phenyl opt. substd. by halo, CF3, alkyl or alkoxy; or R1+R2 = opt. alkyl-substd. 2-5C alkylene; provided that R1 and R2 are not both H.
ES95810271T 1994-05-03 1995-04-25 DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT. Expired - Lifetime ES2109796T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH138594 1994-05-03
CH24595 1995-01-30

Publications (1)

Publication Number Publication Date
ES2109796T3 true ES2109796T3 (en) 1998-01-16

Family

ID=25684008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95810271T Expired - Lifetime ES2109796T3 (en) 1994-05-03 1995-04-25 DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT.

Country Status (21)

Country Link
US (2) US5686457A (en)
EP (1) EP0682027B1 (en)
JP (1) JP3042760B2 (en)
KR (1) KR950031113A (en)
CN (1) CN1128263A (en)
AT (1) ATE159257T1 (en)
AU (1) AU695244B2 (en)
CA (1) CA2148324A1 (en)
CZ (1) CZ113195A3 (en)
DE (1) DE59500788D1 (en)
DK (1) DK0682027T3 (en)
ES (1) ES2109796T3 (en)
FI (1) FI952033A (en)
GR (1) GR3025158T3 (en)
HK (1) HK1002935A1 (en)
HU (1) HUT71818A (en)
IL (1) IL113531A0 (en)
NO (1) NO951684L (en)
NZ (1) NZ272031A (en)
PL (1) PL308426A1 (en)
SK (1) SK56195A3 (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199553T1 (en) * 1994-09-29 2001-03-15 Novartis Erfind Verwalt Gmbh PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES AND THEIR USE
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP0819129B1 (en) * 1995-04-03 2000-08-02 Novartis AG Pyrazole derivatives and processes for the preparation thereof
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
SI9620103A (en) * 1995-07-06 1998-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
CH690773A5 (en) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
TR199801530T2 (en) 1996-02-13 1998-11-23 Zeneca Limited Quinazoline derivatives as VEGF inhibitors.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP4464466B2 (en) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4-anilinoquinazoline derivatives
PL190489B1 (en) 1996-04-12 2005-12-30 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
JP4242928B2 (en) 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト Substituted pyrrolopyrimidine and process for producing the same
JP4205168B2 (en) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト Pyrimidine derivatives and process for producing the same
DE69728688T2 (en) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLE AS AN ANTI-FLAMMING AGENT
BR9713552A (en) * 1996-11-27 2000-01-25 Pfizer Condensed bicyclic pyrimidine derivatives
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
ATE296825T1 (en) * 1997-08-05 2005-06-15 Pfizer Prod Inc 4-AMINOPYRROLE(3,2-D)PYRIMIDINES AS NEUROPEPTIDE RECEPTOR ANTAGONISTS
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE69943144D1 (en) 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AP1411A (en) 1998-06-02 2005-05-10 Osi Pharm Inc Pyrrolo[2,3d] pyrimidine compositions and their use.
ID26698A (en) 1998-06-19 2001-02-01 Pfizer Prod Inc PIROLO COMPOUNDS [2,3-d] PYRIMIDINE
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
CZ2001959A3 (en) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidines functioning as kinase inhibitors
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CN1144786C (en) 1998-09-29 2004-04-07 美国氰胺公司 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
NZ516292A (en) * 1999-05-21 2004-01-30 Bristol Myers Squibb Co Pyrrolotriazine inhibitors of kinases
EP1669071B1 (en) * 1999-05-21 2009-07-22 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
UA72946C2 (en) 1999-11-05 2005-05-16 Астразенека Аб Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DK1235830T3 (en) 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds as protein kinase inhibitors
EE200200711A (en) 2000-06-26 2004-06-15 Pfizer Products Inc. Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE319718T1 (en) 2001-05-14 2006-03-15 Novartis Pharma Gmbh OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE AS MEDICATIONS AGAINST TUMORS
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
CN1523991A (en) * 2001-08-10 2004-08-25 ��˹��ŵ�� Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE60234118D1 (en) 2001-11-30 2009-12-03 Osi Pharm Inc Compounds specific for adenosine A1 and A3 receptors and their applications
GT200200234A (en) * 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
CN1620294A (en) 2001-12-20 2005-05-25 Osi药物公司 Pyrimidine A2b selective antagonist compounds, their synthesis and use
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US6805491B2 (en) * 2002-05-20 2004-10-19 Stratos International, Inc. Stub having an optical fiber
ES2291690T3 (en) * 2002-07-11 2008-03-01 Bayer Pharmaceuticals Corporation FUROPIRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS.
EP1572213A1 (en) 2002-11-26 2005-09-14 Pfizer Products Inc. Method of treatment of transplant rejection
WO2004093812A2 (en) * 2003-04-22 2004-11-04 Irm Llc Compounds that induce neuronal differentiation in embryonic stem cells
WO2005010008A1 (en) * 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20070197559A1 (en) * 2004-03-02 2007-08-23 Rajagopal Bakthavatchalam Aryl substituted purine analogues
WO2005097800A1 (en) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (en) 2004-08-12 2006-06-01 Bristol Myers Squibb Co PROCEDURE FOR PREPARING A COMPOUND OF PYRROLOTRIAZINE ANILINE AS KINASE INHIBITORS
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
JP5302883B2 (en) 2006-04-07 2013-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Thienopyrimidine having MNK1 / MNK2 inhibitory activity for pharmaceutical composition
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP4884570B2 (en) 2008-08-20 2012-02-29 ファイザー・インク Pyrrolo [2,3-d] pyrimidine compound
UY32072A (en) 2008-08-26 2010-03-26 Boehringer Ingelheim Int TIENOPIRIMIDINS FOR PHARMACEUTICAL COMPOSITIONS
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US20120316187A1 (en) 2009-11-13 2012-12-13 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
EA201201191A1 (en) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4- [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2,3-D] PYRIMIDINES THAT HAVE INHIBITING ACTIVITY WITH RESPECT TO MNKL / MNK2 INTENDED FOR PHARMACEUTICAL COMPOSITIONS
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
EP2694515B1 (en) * 2011-04-04 2016-08-17 Pharmascience Inc. Protein kinase inhibitors
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP6297490B2 (en) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド Diagnostic marker
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2873971A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
MD20140130A2 (en) 2012-06-29 2015-04-30 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
MX2017008421A (en) 2014-12-24 2018-03-23 Genentech Inc Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
RS62456B1 (en) 2016-12-22 2021-11-30 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019216409A1 (en) 2018-05-11 2019-11-14 学校法人慶應義塾 Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
MX2020012261A (en) 2018-06-12 2021-03-31 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer.
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
JP2020090482A (en) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Improved synthesis of key intermediate of kras g12c inhibitor compound
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
PE20211475A1 (en) 2018-12-20 2021-08-05 Amgen Inc KIF18A INHIBITORS
MA54546A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
ES2953821T3 (en) 2018-12-20 2023-11-16 Amgen Inc KIF18A inhibitors
MA54547A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
CN113874015A (en) 2018-12-21 2021-12-31 细胞基因公司 Thienopyridine inhibitors of RIPK2
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (en) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド Bicyclic heteroaryl compounds and their use
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114401953A (en) 2019-08-02 2022-04-26 美国安进公司 KIF18A inhibitors
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
EP4054719A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
TW202132314A (en) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras inhibitors
CA3159559A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
PE20230249A1 (en) 2019-11-08 2023-02-07 Revolution Medicines Inc BICYCLIC HETEROARYL COMPOUNDS AND THEIR USES
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
AR120456A1 (en) 2019-11-14 2022-02-16 Amgen Inc ENHANCED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND
JP2023505100A (en) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
BR112022010086A2 (en) 2020-01-07 2022-09-06 Revolution Medicines Inc SHP2 INHIBITOR DOSAGE AND CANCER TREATMENT METHODS
CN115916194A (en) 2020-06-18 2023-04-04 锐新医药公司 Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (en) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. Indole derivatives as RAS inhibitors in the treatment of cancer
CN117396472A (en) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 SOS1 inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CR20230570A (en) 2021-05-05 2024-01-22 Revolution Medicines Inc Ras inhibitors
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and uses thereof
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
TW202340214A (en) 2021-12-17 2023-10-16 美商健臻公司 Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) * 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
GB980515A (en) * 1962-03-01 1965-01-13 Wellcome Found 7-substituted pyrrolo[2,3-d]pyrimidines
US3311628A (en) * 1965-03-09 1967-03-28 Bristol Myers Co Derivatives of pyrrolo [2, 3-d] pyrimidine
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
DE2818676A1 (en) 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg SUBSTITUTED 5,6-DIMETHYLPYRROLO 2,3-D PYRIMIDINE, THE METHOD FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
DE3036390A1 (en) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid
JPS63107966A (en) * 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd Pyrimidine derivative
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
JPH03107966A (en) * 1989-09-22 1991-05-08 Ricoh Co Ltd Developing device
CA2032695A1 (en) * 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
CA2051012C (en) * 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
JPH04141649A (en) * 1990-10-02 1992-05-15 Konica Corp Production of octahedral and 14-faced particle emulsion containing silver chloride
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE4230262A1 (en) * 1992-09-10 1994-03-17 Behringwerke Ag Substituted phenols, processes for their preparation and their use for the treatment of cell proliferation-related diseases
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5543413A (en) * 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
ATE199553T1 (en) * 1994-09-29 2001-03-15 Novartis Erfind Verwalt Gmbh PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES AND THEIR USE
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
SI9620103A (en) * 1995-07-06 1998-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof

Also Published As

Publication number Publication date
IL113531A0 (en) 1995-07-31
DK0682027T3 (en) 1998-05-04
CZ113195A3 (en) 1995-12-13
FI952033A0 (en) 1995-04-28
HUT71818A (en) 1996-02-28
ATE159257T1 (en) 1997-11-15
KR950031113A (en) 1995-12-18
JPH0853454A (en) 1996-02-27
EP0682027A1 (en) 1995-11-15
US5686457A (en) 1997-11-11
JP3042760B2 (en) 2000-05-22
HU9501230D0 (en) 1995-06-28
DE59500788D1 (en) 1997-11-20
AU695244B2 (en) 1998-08-13
EP0682027B1 (en) 1997-10-15
NO951684L (en) 1995-11-06
NO951684D0 (en) 1995-05-02
SK56195A3 (en) 1996-05-08
FI952033A (en) 1995-11-04
US6096749A (en) 2000-08-01
HK1002935A1 (en) 1998-09-25
NZ272031A (en) 1997-01-29
AU1772295A (en) 1995-11-09
CA2148324A1 (en) 1995-11-04
CN1128263A (en) 1996-08-07
GR3025158T3 (en) 1998-02-27
PL308426A1 (en) 1995-11-13

Similar Documents

Publication Publication Date Title
ES2109796T3 (en) DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT.
ES8505673A1 (en) Antibacterial agents.
AU3564395A (en) Pyrrolo(2,3-d)pyrimidines and their use
NZ337121A (en) Pyrazine compounds as good anti-convulsants for the treatment of CNS diseases such as epilepsy
ATE42037T1 (en) PORPHYRINS AND CANCER TREATMENT.
DK374085D0 (en) TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS
EP0235589A3 (en) Use of quinolone and naphthyridine antibiotics for the manufacture of ophthalmic medicaments
ES2111616T3 (en) CYCLOHEXAPEPTIDIL BISAMINE COMPOUNDS.
ES533653A0 (en) PROCEDURE FOR PREPARING PIRAZOL (ARYL) METHANONES
JPS562961A (en) Alphaacarbamoyllpyrrolepropionitrile* its manufacture* pharmaceutic medicine containing same and its therapeutic application
DK310785D0 (en) RUBBER-CONDENSED PYRAZOLO (3,4-D) -PYRIDIN-3-ONES AND SALTS THEREOF, AND THEIR PREPARATION AND USE
AU2482895A (en) Pyrazolyl derivatives, their preparation and their use
AU1815092A (en) Intermediates used in preparation of pyrrolo{1,2-a}-imidazole and pyrrolo{1,2-a}pyridine derivatives
ATE88176T1 (en) 2-HYDROXY-3-ARYLOXY-PROPYLAMINE DERIVATIVES WITH CARDIOVASCULAR ACTIVITIES.
ES8604121A1 (en) Substituted guanidinobenzoic-acid phenyl esters, process for their production and their use as pharmaceutical preparations.
ES2195996T3 (en) CICLOHEXAPEPTIDILO HYDROXIPROPIONITRILE COMPOUNDS.
FI963808A (en) Process for the preparation of (1H-tetrazol-5-yl) tetrazolo (1,5-a) quinolines and naphthyridines
MY101822A (en) (5r,6s,8r)-6-(1-hydroxyethyl)-2-(3r-pyrrolidin-2-one-3-yl-)thiopenem-3-carboxylic acid.
FR2267102A1 (en) 2,6-Di(branched alkylamino)pyridines - for treatment of fatty degeneration and diabetes
ATE88706T1 (en) (1R,5S,6S)-2-THIO-6((R)-1-HYDROXYETHYL>-1-METHYL-CARBAPENEM CARBONIC ACID DERIVATIVES SUBSTITUTED IN THE 2-POSITION.
AU2427188A (en) Enhancing drug delivery to the brain
ES8600767A1 (en) A carbapenem compound, preparation and use.
SU1607351A1 (en) 3-BENZOIL-1-PHENYL-1N-PYRAZOLO [3,4-b] CHINOXALINE THAT IS ANTILLOUS ANTI-STATUS ACTIVITY

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 682027

Country of ref document: ES